Steven Holm

Steven focuses his practice on advising both public and private companies and investors across South and Southeast Asia on strategic transactions and corporate governance.

Steven is counsel to companies across a broad range of industries and ranging from start-ups to well established companies. He is passionate about the “bits & atoms” Life Sciences, AgTech, DeepTech and CleanTech ecosystem in Southeast Asia and diversifying the new economy ecosystem.

Steven has significant experience in private financings, IPOs, deSPAC transactions, crossover rounds, follow-on offerings, debt financing rights issues and ongoing securities law compliance with expertise in introducing regional companies to international markets. He also advises venture capital and private equity funds and investment banking firms in connection with financings.

Prior to joining Cooley, Steven worked in the Singapore and London offices of Milbank and Shearman & Sterling, respectively.

Representative Matters*:

Life Sciences & DeepTech

• Enlitic on its ASX IPO and subsequent follow-on capital raise and bolt-on acquisitions
• Opthea on its several follow-on capital raisings and strategic transaction considerations
• ASLAN Pharmaceuticals in its follow-on capital raisings, public company matters and IP backed debt facility
• Hummingbird Bioscience in its private fundraisings and strategic transactions.
• eFishery on its Series D Financing raising $200 million Summit Healthcare (SPAC) in its US$849 million merger with YS Biopharma and the deSPAC listing on Nasdaq
• Summit Healthcare (SPAC) in its US$849 million merger with YS Biopharma and the deSPAC listing on Nasdaq
• Welsbach (SPAC) in its proposed merger listing with WaveTech, a battery technology company, and deSPAC listing on Nasdaq
• The lead investor in 1NHealth’s Series A private financing
• World View in its proposed merger and deSPAC listing on NYSE 
• A Singapore-based medical devices company in its proposed US and Singapore IPOs 
• An Indonesia-based AgTech platform in their private financings and shareholder engagement strategy
• Several APAC-headquarters and US listed biotech and device companies in their public company matters
• Numerous pre-seed TechBio, AgBio & CleanTech companies in their founder relationship structuring, investor engagements and pilot arrangements with multinationals 

Technology

• Life360 in its US$179 million Nasdaq U.S. IPO and uplisting from ASX
• Bitdeer Technologies Group in its US$1.18 billion merger with Blue Safari (SPAC) and deSPAC listing on Nasdaq
• Bukalapak in its US$1.5 billion 144A Indonesian IPO*
• Triterras in one of the first Asian deSPAC transactions*
• MoneyHero in its ongoing public company matters
• Aetherium (SPAC) in its proposed US$1.15 billion merger with an arm of AirAsia and deSPAC listing
• FinAccel on its $270 million Series D private financing and proposed deSPAC transaction
• Fluid in its Series A private financing
• Tiga Acquisition Corp. in its SPAC IPO and eventual US$2.1 billion deSPAC transaction with Grindr*
• 20Cube Logistics in their proposed deSPAC transaction
• A Singapore-based e-commerce service provider in its ongoing IPO transaction
• A US-listed SaaS company on its proposed follow-on offering and secondary listing on the SGX
• Several fintech lenders in their private debt financing matters 
• An Indonesia-based LogisticsTech platform in their private financings and shareholder engagement strategy
• Several US-based SaaS multinationals on the impact of Singapore’s LNLCo regulation on their APAC holding companies and global ESG reporting strategy
• Several ASEAN e-wallet providers in their private financings, shareholder engagement and exit considerations
• Numerous Venture Capital funds in their portfolio’s post-listing shareholder reporting and liquidity matters

Other Industry Verticals*

• Bank Rakyat Indonesia in its 144A Indonesian rights issue to fund a material acquisition
• The underwriters in the Philippines IPO of DDMP REIT, the 2nd REIT IPO in the Philippines using an innovative structure
• Summarecon Agung in its Reg S only exclusionary Rights Issue and Reg S secondary placement
• Tele2 in its US IPO on Form F-4, following its acquisition of Com Hem
• GE Oil & Gas in its spin-out of GE and merger with Baker Hughes on Form S-4
• The initial purchasers in Waberer’s 144A Hungarian IPO, the largest IPO in Hungary since 1998 and first CEE sponsor IPO exit
• Lecta in its proposed 144A Luxembourg IPO
• The underwriters in NatWest Group (fka The Royal Bank of Scotland Group)’s F-3 shelf takedowns and F-3 renewal
• The underwriters in ArcelorMittal’s F-3 shelf takedown
• The initial purchasers in several PETRONAS 144A GMTN program updates and takedowns
• Indofood CBP in its inaugural Reg S issuance; one of the first investment grade debt issuances by a non- state linked Indonesian company
• Ongoing SEC compliance and continuous disclosure for multiple foreign private issuers and certain domestic registrants

*includes experience from prior firms